Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse by Moskowitz, Craig H., Walewski, Jan, Nademanee, Auayporn, Masszi, Tamas, Agura, Edward, Holowiecki, Jerzy, Abidi, Muneer H., Chen, Andy I., Stiff, Patrick, Viviani, Simonetta, Bachanova, Veronika, Sureda, Anna, McClendon, Teresa, Lee, Connie, Lisano, Julie, Sweetenham, John

Get full text